Premium
A double‐blind study of neurotropin in patients with acute ischemic stroke
Author(s) -
Reuck J.,
Decoo D.,
Vanderdonckt P.,
Dallenga A.,
Ceusters W.,
Kalala J. P.,
Meulemeester K.,
Abdullah J.,
Santens P.,
Huybrechts J.,
Spiers R.,
Bleecker J.,
Tack I.,
Tack E.,
Vogels C.,
Boon P.
Publication year - 1994
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1994.tb02643.x
Subject(s) - medicine , placebo , stroke (engine) , anesthesia , acute stroke , clinical trial , randomized controlled trial , infarction , surgery , myocardial infarction , pathology , mechanical engineering , alternative medicine , tissue plasminogen activator , engineering
Neurotropin was found to reduce brain oedema in an experimental model of brain infarction in the guinea‐pig. A randomized double‐blind controlled trial with Neurotropin was performed in 220 patients admitted within 24 h after an acute ischemic stroke. 35 of the neurotropin and 41 of the placebo‐randomized patients had to be excluded. 10 included patients in the neurotropin and 13 in the placebo‐treated group died within the study period of 15 days. A better clinical outcome was observed in the 65 included surviving neurotropin compared with the 56 placebo‐treated patients. The size of the infarct and of the oedema zones was significantly more decreased on CTscans from Day 11 compared with Day 3 after stroke in the neurotropin than in the placebo treated group. Neurotropin is helpful in treating brain oedema, related to acute ischemic stroke.